DLST Antibody, FITC conjugated

Code CSB-PA861526LC01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) DLST Polyclonal antibody
Uniprot No.
Target Names
DLST
Alternative Names
2-oxoglutarate dehydrogenase complex component E2 antibody; Dihydrolipoamide S succinyltransferase (E2 component of 2 oxo glutarate complex) antibody; Dihydrolipoamide S succinyltransferase antibody; Dihydrolipoamide succinyltransferase component of 2 oxoglutarate dehydrogenase complex antibody; Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex antibody; Dihydrolipoyllysine residue succinyltransferase component of 2 oxoglutarate dehydrogenase complex antibody; Dihydrolipoyllysine residue succinyltransferase component of 2 oxoglutarate dehydrogenase complex mitochondrial antibody; Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex antibody; Dlst antibody; DLTS antibody; E2 antibody; E2K antibody; mitochondrial antibody; ODO2_HUMAN antibody; OGDC-E2 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial protein (76-225AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
FITC
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Dihydrolipoamide succinyltransferase (E2) component of the 2-oxoglutarate dehydrogenase complex. The 2-oxoglutarate dehydrogenase complex catalyzes the overall conversion of 2-oxoglutarate to succinyl-CoA and CO(2). The 2-oxoglutarate dehydrogenase complex is mainly active in the mitochondrion. A fraction of the 2-oxoglutarate dehydrogenase complex also localizes in the nucleus and is required for lysine succinylation of histones: associates with KAT2A on chromatin and provides succinyl-CoA to histone succinyltransferase KAT2A.
Gene References into Functions
  1. RNAi knockdown of DLST led to decreased cell viability and induction of apoptosis in human T-ALL cell lines PMID: 26876595
  2. 2-oxoglutarate dehydrogenase complex (OGDHC), the key regulatory enzyme of Krebs cycle. [review] PMID: 22235656
  3. Data show that the dihydrolipoamide succinyltransferase gene is bifunctional, and truncated mRNA transcribed from it contributes to the biogenesis of the mitochondrial respiratory complexes. PMID: 12805207
  4. Association between late-onset Alzheimer disease shows strong linkage disequilibrium across the DLST locus. PMID: 15038610
Subcellular Location
Mitochondrion matrix. Nucleus.
Protein Families
2-oxoacid dehydrogenase family
Database Links

HGNC: 2911

OMIM: 126063

KEGG: hsa:1743

STRING: 9606.ENSP00000335304

UniGene: Hs.525459

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*